Abstract
The EMEA gets good grades, but has room for improvement.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Office for Official Publications of the European Communities, 2 Rue de Mercier, L-2985, Luxembourg.
Acknowledgements
The author wishes to acknowledge the EMEA home page and annual reports as the source of much of the data provided. The assistance of various EMEA staff is also acknowledged, as is that of the regulatory affairs personnel of various companies who responded to an informal survey carried out in preparation for this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walsh, G. Drug approval in Europe. Nat Biotechnol 17, 237–240 (1999). https://doi.org/10.1038/6977
Issue Date:
DOI: https://doi.org/10.1038/6977
This article is cited by
-
Walking the drug regulatory tightrope
Nature Biotechnology (2003)
